Quest Diagnostics Inc vs Illinois Tool Works Inc. — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Illinois Tool Works Inc. trades at $264.18 (market cap $74.38B). The key difference: Illinois Tool Works Inc. is far larger — about 2.9× Quest Diagnostics Inc's market cap, and Illinois Tool Works Inc. pays the higher dividend (2.63%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Illinois Tool Works Inc. for 67 Days on average.
| DGX | ITW | |
|---|---|---|
Market Cap | $25.48B | $74.38B |
Volume | 941,866 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $247.45 | $299.60 |
52-Week Low | $173.49 | $241.07 |
Typical Hold Time | 56 Days | 67 Days |
Enterprise Value | $31.23B | $83.23B |
Dividend Yield | 1.49% | 2.63% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
ITW trades at $261.15, down 2.24% on the day, with a bearish technical signal from moving averages. The company demonstrates strong profitability with a 19.39% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its status as a Dividend King, having raised its dividend to $1.72 per share, with a forward yield of approximately 2.57%.
The outlook is mixed; strong fundamentals and a consensus price target of $280.14 suggest upside potential, but a high P/E ratio of 23.65 and bearish technical indicators indicate near-term pressure. Key risks include economic sensitivity and rising debt levels, while institutional buying provides some support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →